ArticleOphthalmology and therapy2025
Distinct Pathogenic Mechanisms of Neurodegeneration in Pachychoroid Pigment Epitheliopathy Versus Intermediate Age-Related Macular Degeneration.
Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pachychoroid pigment epitheliopathy: long-term structural changes and risk factors for disease evolution.Eye (London, England) · 2026Article
- Choroidal Vascular Findings in a Case of Multifocal Geographic Atrophy: A Clinicopathologic Correlation.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo investigate distinct neurodegeneration mechanisms in pachychoroid pigment epitheliopathy (PPE) versus age-related macular degeneration (AMD) using quantitative optical coherence tomography (OCT) with age-matched controls.
methodsThis cross-sectional study of 184 subjects included 50 age-matched controls (25 young: 47-63 years; 25 elderly: 67-83 years), 57 PPE patients (47-63 years), 39 AMD drusen patients (64-80 years), and 38 AMD reticular pseudodrusen patients (67-83 years). Primary outcomes included ganglion cell layer-inner plexiform layer (GCL-IPL) thickness, subfoveal choroidal thickness, and choroidal volume using swept-source OCT.
resultsAll pathologic conditions showed significant neurodegeneration versus age-matched controls (p < 0.001). PPE demonstrated choroidal thickening (410.5 ± 32.9 μm vs. 306.0 ± 10.8 μm controls) with inverse choroidal-neural correlations (r = -0.52 to -0.61, p < 0.001). AMD variants showed choroidal thinning (187-238 μm vs. 277 μm elderly controls) with positive correlations (drusen: r = +0.43, p = 0.006; RPD: r = +0.68, p < 0.001).
conclusionsTwo distinct pathways cause neurodegeneration: compressive (PPE: choroidal thickening → choriocapillaris compression → neurodegeneration) and ischemic (AMD: choroidal thinning → hypoperfusion → neurodegeneration).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.